• concept
ApoB & Lipid Longevity
ApoB, lifetime LDL exposure, and protein/lipid trade-offs for long-term cardiovascular risk.
2 well-supported · 0 disputed. This shows how settled each sub-question is, not whether ApoB & Lipid Longevity is "good." Direction lives in each claim below.
The 5 claims about ApoB & Lipid Longevity
Each keeps its own verdict — we never average them away.
Is ApoB a better heart-attack risk predictor than standard LDL cholesterol?
Strong support Yes — ApoB captures atherogenic particle number and outperforms LDL-C when the two disagree, though absolute gain over non-HDL-C is modest and it does not overturn LDL-C's causal role.
If you start lowering LDL/ApoB aggressively in your 20s-30s, do you cut lifetime heart-disease risk?
Strong support The cumulative-exposure MODEL is strongly supported by genetics (Mendelian randomization) and statin trials, but no completed RCT has tested drug-lowering starting in the 20s-30s — the specific early-start claim is a well-reasoned extrapolation, not proven.
Does lots of animal protein in midlife shorten your life?
Contested Possibly — midlife intake leans toward higher risk in several cohorts, but it's inconsistent and appears to reverse after 65.
Is high protein bad for you before 65 but good after 65?
Contested This age-flip pattern comes largely from one Longo-group NHANES analysis; larger independent meta-analyses find mainly that plant protein is protective and animal protein modestly harmful across ages, without cleanly replicating the under/over-65 reversal.
Does eating a lot of protein clog arteries through a leucine/mTOR pathway?
Contested Real, well-characterized mechanism with a leucine threshold and some human monocyte/macrophage data — but the atherosclerosis outcome itself is shown only in mice; there is NO human cardiovascular-endpoint trial.
Educational only, not medical advice. Hub descriptions are curated for honesty; see the methodology.